EGFR and neoplasm: incorporated an 806-based scFv into a CAR backbone and demonstrated that these EGFR806-CAR T cells conferred high anti-tumor potency in a glioblastoma in vivo model but no on-target/off-tumor activation in EGFR-positive human teratomas in the same animals.14